Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study

被引：12

作者：

Richardson, Paul ^{[1
]}

Jagannath, Sundaf ^{[2
]}

Raje, Noopur ^{[3
]}

Jakubowiak, Andrzej ^{[4
]}

Lonial, Sagar ^{[5
]}

Ghobrial, Irene ^{[6
]}

Schlossman, Robert ^{[1
]}

Mazumder, Amitabha ^{[2
]}

Munshi, Nikhil ^{[1
]}

Colson, Kathleen ^{[1
]}

McKenney, Mary ^{[1
]}

Farrell, Melissa ^{[1
]}

Lunde, Laura ^{[1
]}

Giove, Lawrence ^{[2
]}

Kaster, Sarah

Mitsiades, Constantine ^{[1
]}

Hideshima, Teru ^{[1
]}

Knight, Robert ^{[6
]}

Esseltine, Dixie-Lee ^{[7
]}

Anderson, Kenneth ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] St Vincents Comprehens Canc Ctr, New York, NY USA

[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[4] Univ Michigan, Ann Arbor, MI 48109 USA

[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[6] Celgene Corp, Summit, NJ USA

[7] Millennium Pharmaceut Inc, Cambridge, MA USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.2714.2714

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2714

引用

页码：797A / 797A

页数：1

共 50 条

[1] Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
Anderson, K. C.
Jagannath, S.
Jakubowiak, A.
Lonial, S.
Raje, N.
Schlossman, R.
Munshi, N.
Knight, R.
Esseltine, D.
Richardson, P. G.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[2] Phase 2 study of Rev/Vel/Dex in relapsed/refractory MM
Richardson, P. G.
Jagannath, S.
Raje, N.
Ghobrial, I.
Schlossman, R. L.
Mazumder, A.
Munshi, N. C.
VeSole, D.
Colson, K.
McKenney, M. L.
Farrell, M. G.
Warren, D. L.
Lunde, L. E.
Giove, L.
Kaster, S.
Shea, K.
Jakubowiak, A.
Alsina, M.
Lonial, S.
Mitsiades, C. S.
Hideshima, T.
Knight, R.
Myers, T.
Anderson, K. C.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 171 - 171
[3] Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): Preliminary results of a phase 1/2 study
Richardson, Paul
Jagannath, Sundar
Raje, Noopur
Jakubowiak, Andrzej
Lonial, Sagar
Avigan, David
Ghobrial, Irene
Schlossman, Robert
Mazumder, Amitabha
Munshi, Nikhil
Joyce, Robin
Doss, Deborah
Warren, Diane
Hayes, Stephen
Giove, Lawrence
Kaster, S.
Delaney, Carol
Lauria, Marisa
Mitsiades, Constantine
Hideshima, Teru
Knight, Robert
Esseltine, Dixie-Lee
Anderson, Kenneth
BLOOD, 2007, 110 (11) : 63A - 63A
[4] Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study
Anderson, K. C.
Jagannath, S.
Jakubowiak, A.
Lonial, S.
Raje, N.
Alsina, M.
Ghobrial, I.
Knight, R.
Esseltine, D.
Richardson, P.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[5] Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): Final results of a multicenter phase 1 trial.
Richardson, Paul G.
Jagannath, S.
Avigan, D. E.
Alsina, M.
Schlossman, R. L.
Mazumder, A.
Munshi, N. C.
Ghobrial, I.
Doss, D.
McKenney, M. L.
Farrell, M. G.
Warren, D. L.
Lunde, L. E.
Gourley, B.
Vaccaro, S.
Delaney, C.
Pountney, S.
Mitsiades, C. S.
Hideshima, T.
Byrne, C.
Knight, R.
Birner, A.
Myers, T.
Weller, E.
Anderson, K. C.
BLOOD, 2006, 108 (11) : 124A - 124A
[6] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
Lacy, Martha Q.
LaPlant, Betsy R.
Laumann, Kristina M.
Kumar, Shaji
Gertz, Morie A.
Hayman, Suzanne R.
Buadi, Francis
Dispenzieri, Angela
Lust, John A.
Kapoor, Prashant
Leung, Nelson
Russell, Stephen J.
Dingli, David
Gonsalves, Wilson I.
Fonseca, Rafael
Bergsagel, P. Leif
Roy, Vivek
Sher, Taimur
Ailawadhi, Sikander
Chanan-Khan, Asher
Stewart, A. Keith
Reeder, Craig B.
Rajkumar, S. Vincent
Mikhael, Joseph R.
BLOOD, 2014, 124 (21)
[7] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
Yasuo Mori
Ilseung Choi
Goichi Yoshimoto
Tsuyoshi Muta
Satoshi Yamasaki
Kazuki Tanimoto
Tomohiko Kamimura
Hiromi Iwasaki
Ryosuke Ogawa
Koichi Akashi
Toshihiro Miyamoto
International Journal of Hematology, 2020, 111 : 673 - 680
[8] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
Mori, Yasuo
Choi, Ilseung
Yoshimoto, Goichi
Muta, Tsuyoshi
Yamasaki, Satoshi
Tanimoto, Kazuki
Kamimura, Tomohiko
Iwasaki, Hiromi
Ogawa, Ryosuke
Akashi, Koichi
Miyamoto, Toshihiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 673 - 680
[9] Phase II trial of bevacizumab combined with low dose dexamethasone and lenalidomide (BEV/REV/DEX) for relapsed or refractory myeloma (MM)
Raschko, Martha
Markovina, Stephanie
Miyamoto, Shigeki
Longo, Walter
Williams, Eliot
McFarland, Thomas
Wemdli, Jae
Wagner, Elisabeth
Juckett, Mark
Callander, Natalie
BLOOD, 2007, 110 (11) : 355A - 356A
[10] PRELIMINARY RESULTS OF A PHASE I/II STUDY OF CARFILZOMIB, LENALIDOMIDE, VORINOSTAT AND DEXAMETHASONE (QUAD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM)
Bilotti, El
Vesole, D.
Richter, J.
McNeill, A.
Anand, P.
Bednarz, U.
Ivanovski, K.
McBride, L.
Raucci, L.
Batra, V.
Siegel, D.
HAEMATOLOGICA, 2013, 98 : 323 - 324

← 1 2 3 4 5 →